![Pharmacokinetics, Safety and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Multiple Ascending Doses and Effect of Co-Administration of Ketoconazole in Healthy Subjects Pharmacokinetics, Safety and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Multiple Ascending Doses and Effect of Co-Administration of Ketoconazole in Healthy Subjects](https://www.natap.org/2009/images/050609/SD-2.gif)
Pharmacokinetics, Safety and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Multiple Ascending Doses and Effect of Co-Administration of Ketoconazole in Healthy Subjects
On Biostatistics and Clinical Trials: SAD and MAD: Single Ascending Dose and Multiple Ascending Dose first-in-human studies
![A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers | BMC Pulmonary A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers | BMC Pulmonary](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12890-018-0763-9/MediaObjects/12890_2018_763_Fig1_HTML.png)
A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers | BMC Pulmonary
![Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies | SpringerLink Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40262-020-00911-0/MediaObjects/40262_2020_911_Fig2_HTML.png)
Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies | SpringerLink
![Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending- Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers | Antimicrobial ... Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending- Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers | Antimicrobial ...](https://journals.asm.org/cms/10.1128/AAC.00607-16/asset/2831b6ce-f896-4ad2-85f0-ba9c866e5c07/assets/graphic/zac0091654860001.jpeg)
Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending- Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers | Antimicrobial ...
![Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies | SpringerLink Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40262-020-00911-0/MediaObjects/40262_2020_911_Fig1_HTML.png)
Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies | SpringerLink
![Traditional Process First in Human Single Ascending Dose Multiple Ascending Dose U.S.A. Japan Phase II Phase III NDA in Japan Phase II Phase III NDA in. - ppt download Traditional Process First in Human Single Ascending Dose Multiple Ascending Dose U.S.A. Japan Phase II Phase III NDA in Japan Phase II Phase III NDA in. - ppt download](https://slideplayer.com/4594482/15/images/slide_1.jpg)
Traditional Process First in Human Single Ascending Dose Multiple Ascending Dose U.S.A. Japan Phase II Phase III NDA in Japan Phase II Phase III NDA in. - ppt download
![Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration - ScienceDirect Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2468653016301750-figs1.jpg)
Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration - ScienceDirect
![Single and multiple ascending dose GS-9256 and GS-9451 clinical trial... | Download Scientific Diagram Single and multiple ascending dose GS-9256 and GS-9451 clinical trial... | Download Scientific Diagram](https://www.researchgate.net/publication/230573915/figure/fig1/AS:300770919501828@1448720783688/Single-and-multiple-ascending-dose-GS-9256-and-GS-9451-clinical-trial-designs.png)
Single and multiple ascending dose GS-9256 and GS-9451 clinical trial... | Download Scientific Diagram
![A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers | BMC Pulmonary A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers | BMC Pulmonary](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12890-018-0763-9/MediaObjects/12890_2018_763_Fig3_HTML.png)
A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers | BMC Pulmonary
On Biostatistics and Clinical Trials: SAD and MAD: Single Ascending Dose and Multiple Ascending Dose first-in-human studies
![Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers | Hypertension Research Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers | Hypertension Research](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41440-022-01070-4/MediaObjects/41440_2022_1070_Figa_HTML.png)
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers | Hypertension Research
![example single ascending dose study design incorporating a CsF-sampling... | Download Scientific Diagram example single ascending dose study design incorporating a CsF-sampling... | Download Scientific Diagram](https://www.researchgate.net/publication/259269580/figure/fig1/AS:351205852237824@1460745408110/example-single-ascending-dose-study-design-incorporating-a-CsF-sampling-dynabridging.png)
example single ascending dose study design incorporating a CsF-sampling... | Download Scientific Diagram
![A First‐in‐Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers - Hazan - 2020 - Clinical Pharmacology in Drug Development - Wiley Online Library A First‐in‐Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers - Hazan - 2020 - Clinical Pharmacology in Drug Development - Wiley Online Library](https://accp1.onlinelibrary.wiley.com/cms/asset/43761d42-355b-4e86-97ab-0cf6dd994e32/cpdd720-fig-0002-m.jpg)
A First‐in‐Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers - Hazan - 2020 - Clinical Pharmacology in Drug Development - Wiley Online Library
![Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota | Antimicrobial Agents and Chemotherapy Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota | Antimicrobial Agents and Chemotherapy](https://journals.asm.org/cms/10.1128/AAC.01395-19/asset/95f59352-97b0-47d8-9045-7db922e49b35/assets/graphic/aac.01395-19-f0001.jpeg)
Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota | Antimicrobial Agents and Chemotherapy
![Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age - ScienceDirect Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0149291815011777-gr1.jpg)
Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age - ScienceDirect
![ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER](https://www.natap.org/2008/images/042508/mult-1.gif)